Boston Scientific (BSX) Reports In-Line Q3 EPS, Offers Q4 Guidance

Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.31, in-line with the analyst estimate of $0.31. Revenue for the quarter came in at $2.22 billion versus the consensus estimate of $2.21 billion.

GUIDANCE:

Boston Scientific sees Q4 2017 EPS of $0.32-$0.35, versus the consensus of $0.34. Boston Scientific sees Q4 2017 revenue of $2.345-2.375 billion, versus the consensus of $2.33 billion.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Is the global equity rally broadening? UBS weighs in
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance